Key result
Dapagliflozin is linked to better real-world HFrEF outcomes, especially in congestive hemodynamic profiles.
Observational
Answers are grounded in this paper and cite their sources.
May guide congestion-based dapagliflozin selection in HFrEF; leaves open randomized confirmation of profile-specific effects.
We demonstrate that Dapagliflozin is rapidly effective in an HFrEF real-world population; furthermore, the more significant effect is recorded in HFrEF patients with a congestive profile (B and D), supporting the introduction of Dapagliflozin in patients with a congestive profile and a worse prognosis. In conclusion, our data suggest evaluating the patient's hemodynamic state beyond LVEF in HFrEF.
No takes yet. Share an insight, caveat, or question.
Loria et al. (2024) conducted an observational in Heart failure with reduced ejection fraction (HFrEF). Dapagliflozin was evaluated. Dapagliflozin was effective in a real-world HFrEF population, with a more significant effect recorded in patients with a congestive hemodynamic profile (B and D).
Synapse has enriched 10 related papers. Consider them for comparative context: